Chiara R. Mancinelli

Brescia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Risk factors for disease generalization in acetylcholine receptor antibody-positive ocular myasthenia: a multicenter retrospective study.

Risk factors for disease generalization in acetylcholine receptor antibody-positive ocular myasthenia: a multicenter retrospective study.

Journal: Frontiers in neurology

Published: February 02, 2026

Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and Discrepancies.

Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and Discrepancies.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 19, 2025

Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab.

Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab.

Journal: Journal of neuroimmunology

Published: June 27, 2023

SARS-CoV-2 antibodies in inflammatory neurological conditions: a multicentre retrospective comparative study.

SARS-CoV-2 antibodies in inflammatory neurological conditions: a multicentre retrospective comparative study.

Journal: Immunologic research

Published: February 16, 2023

Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?

Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?

Journal: Frontiers in neurology

Published: September 19, 2022

Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study.

Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: August 21, 2022

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.

Journal: Multiple sclerosis and related disorders

Published: October 16, 2021

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology.

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology.

Journal: Therapeutics and clinical risk management

Published: April 06, 2021

NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders.

NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders.

Journal: Multiple sclerosis and related disorders

Published: November 09, 2020

Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.

Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 05, 2020

Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up.

Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up.

Journal: EClinicalMedicine

Published: May 19, 2020

Diagnostic features of initial demyelinating events associated with serum MOG-IgG.

Diagnostic features of initial demyelinating events associated with serum MOG-IgG.

Journal: Journal of neuroimmunology

Published: April 17, 2020

Showing 1-12 of 33

Last Updated: 09/26/2026